At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Achira is engaged in development and commercialization of PoC medical test kits in India
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Subscribe To Our Newsletter & Stay Updated